DAIC

MAY 30, 2024

Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE). stent expansion at Maximum Calcium Site 96.7% interventional cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium. . stent expansion at Maximum Calcium Site 96.7%

Stents 105

Stents Stent Peripheral Arterial Disease Cardiovascular Disease 105

DAIC

JUNE 18, 2024

FDA Breakthrough Device Designation accelerates the review process for novel technologies that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as CAD, which impacts 7.8% Stent Related Adverse Events greater than 1 Year After PCI. of the U.S. population.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stents Stent 105

The British Journal of Cardiology

AUGUST 1, 2024

Large-scale observational data have demonstrated a robust, independent association of elevated lipoprotein(a) (Lp[a]) levels with atherosclerotic cardiovascular disease (CVD), stroke, and peripheral artery disease.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Myocardial Infarction Plaque Cardiovascular Disease 40

DAIC

APRIL 5, 2024

With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD).

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105